logo
Have you noticed smoking is making a comeback? I hate that. I love that.

Have you noticed smoking is making a comeback? I hate that. I love that.

Yahoo24-07-2025
The sight of snuffed cigarette butts in an ashtray might feel jarringly anachronistic these days, given successful efforts to curtail the smelly act for decades.
Nonetheless, we're edging toward a resurgence, at least in popular culture, of the classic combustion of an old-school cigarette, even if the Centers for Disease Control and Prevention assures us rates aren't yet increasing. Unfortunately, I've fallen into the quiet resurgence.
I'm a 46-year-old diabetic who tries to be healthy, yet after quitting 20 years ago, I find myself back in the alley occasionally (always shamefully) puffing as I hold pleasure and consequence in the same breath. My friends call it nostalgia. I think it's deeper – a defiant exhale of the angst and authenticity I crave in an uncertain world.
Smoking was eradicated. Now it's creeping back into the mainstream.
The historical canon of smoking is well-documented from early 20th century glamour and association with sophistication, rebellion and artistic freedom – see flappers, film noir, World War II soldiers, the Beat Generation, the Marlboro Man and Bob Dylan.
I grew up in the haze of the 1990s when smoking wasn't just a habit, it was a personality – raw and rebellious – butts smeared with Courtney Love's red lipstick, the thrift-store fantasy of "Reality Bites," the sultry detachment of Mia Wallace in "Pulp Fiction."
But smoking fell out of favor over the past several decades, transforming the cigarette from an emblem of cool into a symbol of a bygone era, fraught with undeniable health consequences. Increased spending on public health campaigns successfully shifted public perception in the 1990s and early 2000s as tobacco control media campaigns vilified the act.
Opinion: Is it Alzheimer's or am I just getting old? Here's how to find an answer.
In 1998, federal law prohibited paid smoking product placement on TV and in the movies, and subsequent smoking bans made it difficult to light up where secondhand smoke might blow.
Taxes made cigarettes pricey, and in 2007, the Motion Picture Association of America began considering cigarette use as a factor in film ratings.
Meanwhile, I managed to quit smoking while navigating my career and a second marriage, as anti-smoking campaigns gained traction and thankfully weakened tobacco's power.
Decades later, the old-school act of combusting nicotine is back in the zeitgeist. The New York Times recently reported on the aesthetic resurgence of smoking, and even the Republican Party brought the act back to the U.S. Capitol in 2023.
Eight in 10 of the 2025 Oscar best picture nominees featured tobacco imagery. In the new Netflix show 'Too Much,' the character Felix practically begs you to tell him smoking isn't cool, as he puffs between his nail-polished fingers and we swoon.
Mistrust of institutions and our angst are why smoking is back
This cultural phenomenon unfolds against a backdrop of deep and precipitous institutional distrust in the U.S. government and a decline in trust across various sectors from 2021 to 2024, including pharmacies, hospitals, social service agencies, fire departments, universities, police departments and public health departments.
Concurrent to these visual cues of lighting up, global anti-smoking efforts are quietly being defunded in favor of even bigger world problems. Without dedicated efforts to keep smokers focused on the undeniable health consequences, are we soon to face an even bigger health crisis? Recent legislation will surely compromise health care for 17 million Americans in the near term.
Opinion: I'm taking a stand against jacked-up airline fees by taking the middle seat
This rebirth points to a deeper longing for control. This stance was well-spun by Kurt Vonnegut when he said, 'The public health authorities never mention the main reason many Americans have for smoking heavily, which is that smoking is a fairly sure, fairly honorable form of suicide.'
In this chosen ritual, however infrequent, I signal a visceral middle finger to ambient anxieties and constant demands for optimization. I scroll my phone anxiously as I'm bombarded by news that's not immediately credible, often a polarized take on fleeting democratic norms.
Smoking is terrible for my health. But it helps feed my need to rebel.
Smoking offers a palpable pause, a singular moment of physical presence in an existence mediated by the ever-present pressure of political machinations. And when those threats feel ambient and involuntary, smoking is a sensory language all its own, where the health consequences almost fade to black (like my lungs) as I relish each tantalizing feature of personal agency.
Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store.
If I asked my therapist why I returned to a pack of Kool 100 Milds as a way to subconsciously control the world's chaos, she'd likely say it's like thumb sucking, a childish habit that I need to eradicate – immediately.
I can't disagree. Smoking is awful for my health. Still, the choice to engage with a known threat paradoxically feels safer than the chaos beyond my control, where fundamental freedoms, like the right to bodily autonomy, are increasingly debated and denied. It speaks to my desire for imperfection, a reclaiming of agency over my body, and deliberate choices in defiance of a societal narrative that often conflates moral virtue with absolute health.
For those, like me, who sometimes justify with a 'one or two won't kill me,' it's important to remember all the reasons we quit in the first place. In addition to the risk of lung cancer or worse, I remind myself of the absurdity of Botoxing my forehead wrinkles and injecting Ozempic if I'm willing to suck on a cancer stick.
I put saccharine, bubble-gum flavored vapes and nicotine pouches in this category, too – they're all really bad for our health. There's no dispute on that, whether or not we fully demonize smoking.
And maybe the fact that we all know how bad it is is the problem. Smoking is Chapter 1 of the original anti-authority playbook, creeping back into consciousness the minute we look away. Akin to slipping on my classic black leather jacket, it will never truly go out of style. Society, it seems, once again sanctions both as my potent symbols of defiance in a world rife with involuntary consequences.
Andrea Javor is a freelance writer and marketing executive based in Chicago. She spends her free time playing poker and working on her memoir. Connect with her on Instagram: @AndreaEJavor
You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter.
This article originally appeared on USA TODAY: Is smoking coming back? Cigarettes still hold power over us | Opinion
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Minze Health Appoints Thomas Moore as President and Chief Executive Officer
Minze Health Appoints Thomas Moore as President and Chief Executive Officer

Yahoo

time9 minutes ago

  • Yahoo

Minze Health Appoints Thomas Moore as President and Chief Executive Officer

ANTWERP, Belgium & MINNEAPOLIS, August 12, 2025--(BUSINESS WIRE)--Minze Health, a leader in digital diagnostics and therapeutics for urology, announced today that Thomas Moore has been appointed President and Chief Executive Officer, effective immediately. Moore brings over two decades of commercial leadership in medtech and a proven track record of driving growth, reimbursement, and global market expansion across the U.S. and Europe. Prior to joining Minze, Moore served as Chief Commercial Officer at GT Medical Technologies and executive leadership roles at Ablative Solutions and CVRx, where he played a central role in revitalizing trial enrollment, scaling commercial operations, and raising over $100M in venture funding. His leadership has accelerated pivotal clinical trials, launched novel therapies, and expanded reimbursement in key global markets. "Minze is uniquely positioned to redefine the patient pathway for millions affected by BPH and OAB through our home-based diagnostics and evidence-backed therapeutics," said Moore. "I'm honored to join this world-class team and lead our expansion into the U.S. while advancing strategic partnerships, reimbursement access, and product innovation. The opportunity to make urologic care more accurate, efficient, and accessible has never been more urgent or exciting." Moore's appointment marks a new chapter in Minze's growth trajectory, as the company prepares for commercial scaling, key reimbursement milestones, and Series B fundraising. "Tom is the right leader at the right time," said Steffen Hovard, Executive Chairman of the Board. "He brings a powerful combination of strategic vision, commercial discipline, and passion for patient-centered innovation. We're thrilled to welcome him as CEO and confident he'll accelerate Minze's mission to become the global standard in digital urology care." About Minze Health Minze Health is transforming urology by combining accurate at-home diagnostics, remote monitoring, and digital therapeutics into a single, scalable platform. With CE mark and 510(k) exemptions, Minze's ecosystem supports early diagnosis and personalized care for conditions like BPH and OAB—empowering patients and relieving pressure on overburdened urology systems. For more information, visit View source version on Contacts Media Contact: Thomas MooreCEO, Minze HealthEmail: Phone: +1 763.258.9039 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

SafeRide Health Ranks No. 358 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
SafeRide Health Ranks No. 358 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies

Yahoo

time9 minutes ago

  • Yahoo

SafeRide Health Ranks No. 358 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies

With Three-Year Revenue Growth of 1,118% Percent, SafeRide is redefining transportation as a trusted care delivery lever for Medicaid and Medicare Advantage plans. NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that SafeRide Health is ranked No. 358 on the 2025 Inc. 5000 list, placing it among the top 7% of the fastest-growing private companies in America. SafeRide also earned distinctions as No. 5 in the San Antonio metro area, No. 40 in Texas, and No. 41 in the healthcare sector nationally. The Inc. 5000 provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. "We're honored to be named to the Inc. 5000 list, let alone to the top 500," said Robbins Schrader, CEO and Co-Founder of SafeRide Health. "We've built a team that shows up every day for the members of our partner health plans. This recognition is a tribute to their grit, to their hard work, and to the mission we share: fixing healthcare by getting people to care." SafeRide Health's ranking reflects more than just scale; it represents a transformation in how health plans are closing the gap between healthcare need and access. The company delivers more than 10 million rides annually across all 50 states, partnering with leading Medicaid and Medicare Advantage plans to serve members who depend on timely, reliable, and compliant non-emergency medical transportation. Unlike legacy brokers, SafeRide was built from the ground up to solve problems of fragmentation, missed care, and fraud, waste, and abuse (read related case study). It boasts industry-leading performance metrics, including 99% ride fulfillment and grievance rate below 0.25% of rides, and a platform that combines real-time eligibility, smart trip orchestration, and a credentialed national network to turn transportation into a care-experience lever. That people-first approach has earned national recognition, including a 2025 USA Today Top Workplace award as well as Top Workplace awards for Professional Development, Employee Well-Being, Culture Excellence, and Remote Work—affirming SafeRide's culture as a key driver of its growth and operational excellence. This year's Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. For the full list, company profiles, and a searchable database by industry and location, visit: "Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor in chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." Inc. will celebrate the honorees at the 2025 Inc. 5000 Conference & Gala, taking place October 22–24 in Phoenix, and the top 500 will be listed in the Fall issue of Inc. magazine. Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit About SafeRide HealthSafeRide Health is a technology and services company dedicated to closing the gap between healthcare need and access through modern, scalable non-emergency medical transportation (NEMT). Built for Medicaid and Medicare Advantage populations, SafeRide combines proprietary technology, real-time eligibility, and a nationwide network of credentialed transportation providers to deliver reliable, compliant, and compassionate care access at scale. Trusted by the country's largest payers and provider organizations, SafeRide transforms transportation from a cost center into a strategic lever for outcomes, equity, and member experience. Learn more at Media ContactAshley RobertsSafeRide Health(855) 955-7433mediarelations@ View original content to download multimedia: SOURCE SafeRide Health Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

Yahoo

time9 minutes ago

  • Yahoo

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea BOSTON, August 12, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the launch of a new Founded Entity Celea Therapeutics ("Celea"). Celea's mission is to deliver therapies that transform the lives of people with serious respiratory diseases. Its lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and fatal lung disease. Sven Dethlefs, PhD, has been appointed to lead Celea, bringing deep expertise and a clear vision to accelerate the program's advancement. The launch of Celea reflects PureTech's commitment to advancing differentiated programs through focused, capital-efficient structures with seasoned leadership. Dr. Dethlefs is a proven pharmaceutical executive with more than 25 years of experience in global commercialization, R&D strategy, business development, and operations. He has played a central role at PureTech, driving forward the deupirfenidone program for more than a year. Prior to joining PureTech, Dr. Dethlefs served as CEO of Teva North America, where he oversaw the company's $8 billion specialty branded and generic businesses across the U.S. and Canada. At Teva, he also held senior leadership roles as Global Head of Marketing and Portfolio, Head of Respiratory Medicines, and COO Operations. He played a key role in the successful launch of AUSTEDO®, Teva's blockbuster treatment for Tardive Dyskinesia and Huntington's Disease, which is a deuterated form of tetrabenazine. Prior to joining Teva, Dr. Dethlefs was a partner at McKinsey & Company. He holds a PhD in Biochemistry. Dr. Sven Dethlefs commented: "Bringing meaningful innovation to patients with serious diseases has been a consistent theme throughout my career, and I believe deupirfenidone has the potential to be a true turning point in the treatment of IPF. Our Phase 2b data demonstrated the potential for best-in-class efficacy with a favorable safety and tolerability profile—addressing two of the most critical limitations of current therapies. The strength of the clinical data, combined with the team and mission behind Celea, make this a uniquely compelling opportunity. I'm excited to lead the next phase of development as we work to deliver a new standard of care for people living with IPF and other debilitating lung conditions." PureTech completed a successful Phase 2b trial of deupirfenidone in December 2024. A meeting with the U.S. Food and Drug Administration to discuss these results and the proposed Phase 3 trial design is expected by the end of the third quarter of 2025. Consistent with its capital-efficient innovation model, PureTech is pursuing third-party funding for Celea to advance the program through Phase 3 and potential commercialization. Robert Lyne, PureTech's Interim Chief Executive Officer, added: "The launch of Celea is an important value driver for PureTech. Sven brings deep experience in respiratory medicine and a strong track record of commercial success, including having played a critical role in the growth of AUSTEDO®, a deuterated medicine developed using the same underlying chemistry approach as deupirfenidone. He is uniquely suited to lead Celea and advance this important program." About Deupirfenidone (LYT-100)Deupirfenidone (LYT-100) is in development as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF). It is a deuterated form of pirfenidone, which – along with nintedanib – is one of the two FDA-approved treatments for IPF. Both approved therapies offer only modest efficacy in slowing lung function decline, largely due to tolerability challenges that limit the ability to achieve higher doses that could significantly improve patient outcomes. These limitations have contributed to low treatment uptake and poor adherence, with approximately 25% of people with IPF in the U.S. ever receiving either drug. Despite this, combined peak global sales exceed $5 billion, representing a significant market opportunity in IPF and other fibrotic lung diseases. 1 Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE IPF trial, deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining a favorable safety and tolerability profile. Initial data from an ongoing open-label extension study suggest that this effect may be sustained through at least 52 weeks. These findings support the potential for deupirfenidone to offer a meaningful advance for people living with this progressive and deadly disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic conditions, including progressive fibrosing interstitial lung diseases. About Idiopathic Pulmonary Fibrosis (IPF)Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal lung disease characterized by irreversible scarring of lung tissue that leads to a steady decline in lung function. Median survival following diagnosis is estimated to be two to five years, and currently there is no cure.2 About Celea TherapeuticsCelea Therapeutics is dedicated to delivering transformative treatments for people with serious respiratory diseases. The company's lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. Celea was founded by PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company dedicated to giving life to science. PureTech's innovative R&D model drives the creation of Founded Entities like Celea, enabling the advancement of highly promising medicines to patients in a capital-efficient manner. For more information, please visit and About PureTech HealthPureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. 1 Esbriet peak sales (2020) per Roche 2021 Financial Results & Ofev peak sales (2024) per Boehringer Ingelheim 2024 Financial Results. Ofev sales include those for all approved indications – IPF, PF-ILD, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). 2 Fisher, M., Nathan, S. D., Hill, C., Marshall, J., Dejonckheere, F., Thuresson, P., & Maher, T. M. (2017). Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. Journal of Managed Care & Specialty Pharmacy, 23(3-b Suppl), S17–S24. Cautionary Note Regarding Forward-Looking StatementsThis press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to continued development of and regulatory interactions related to deupirfenidone, the potential of deupirfenidone in IPF and other indications, our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts PureTech Public Relationspublicrelations@ Investor RelationsIR@ UK/EU Media Ben Atwell, Rob Winder+44 (0) 20 3727 1000puretech@ US Media Justin Chen+1 609 578 7230justin@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store